Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAST: Metformin for Low Risk Prostate Cancer
NCT01864096Phase 3Active, not recruiting
- Sponsor
- University Health Network
- Start
- Oct 2013
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liquid metformin (Aspargo Labs) in prostate cancer (PCa) (2 arms), sponsored by University Health Network. Primary endpoint: Time to progression at 3 years. Started Oct 2013; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01864096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01864096.